id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2018-N-2727-0042,FDA,FDA-2018-N-2727,Institutional Review Board Waiver or Alteration of Informed Consent for Minimal Risk Clinical Investigations; Reopening of Comment Period,Proposed Rule,Extension of Comment Period,2019-02-25T05:00:00Z,2019,2,2019-02-25T05:00:00Z,2019-03-08T04:59:59Z,2019-03-09T02:02:09Z,2019-03195,0,0,0900006483aa313c